DataMEDS AI, Inc. ( MEDS ), a healthcare company, said its recently acquired subsidiary, Helomics Corporation, has received a Medicaid coverage determination from Humana for its ChemoFx assay in ...

Child and adolescent obesity has quadrupled since 1990, rising from two per cent to around eight per cent of youngsters in ...

Mirum Pharmaceuticals ( MIRM) announced positive topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for cholestatic pruritus in patients aged six months and older with ...

John Mayer has added more dates to his 2027 Sphere Las Vegas residency due to overwhelming demand. Mayer, who was originally ...

Freshworks Inc. (FRSH), a provider of customer and employee experience software, on Monday said it has agreed to acquire Torii, a software management platform, to expand its Freshservice offering into ...

Hong Kong-based Euro Tech Holdings Co. Ltd. ( CLWT) on Monday announced that it is expanding into Norway through a 50/50 joint venture between its subsidiary Euro Tech Global Pte Ltd, and Sea Clean AS ...

The Labor Department is scheduled to release its report on consumer price inflation on Wednesday, with the annual rate of consumer price growth expected to accelerate to 3.6 percent in September from ...

Following the rebound seen during last Friday's session, stocks may show a lack of direction in early trading on Monday. The ...

Flyte Aviation, Inc. ( VJET ), on Monday posted its preliminary third-quarter revenue of about $2.15 million, that more than doubled from $1.02 million in the second quarter.

Clearmind Medicine ( CMND) announced that its 51%-owned subsidiary, Charging Robotics Ltd., has launched a next-generation automated electric vehicle charging platform designed for robotaxis, ...

Conducted by the company's subsidiary RayzeBio, Inc., the study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded ...

Fate's lead autoimmune program, FT819, is being evaluated in multiple indications, including refractory lupus nephritis in the Phase 2 RECLAIM-LN trial. The company is also evaluating FT839 in a Phase ...